Initiates Coverage on Pulmatrix (NASDAQ:PULM)

Equities researchers at began coverage on shares of Pulmatrix (NASDAQ:PULMGet Rating) in a research report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Up 0.6 %

Shares of Pulmatrix stock opened at $4.68 on Wednesday. The company’s 50-day moving average price is $4.61 and its two-hundred day moving average price is $5.61. Pulmatrix has a 52 week low of $4.03 and a 52 week high of $20.80.

Institutional Trading of Pulmatrix

Several institutional investors and hedge funds have recently bought and sold shares of PULM. Murchinson Ltd. acquired a new stake in Pulmatrix during the 4th quarter worth about $44,000. Parallax Volatility Advisers L.P. acquired a new stake in Pulmatrix during the 4th quarter worth about $43,000. Citadel Advisors LLC acquired a new stake in Pulmatrix during the 2nd quarter worth about $141,000. Finally, Renaissance Technologies LLC raised its holdings in Pulmatrix by 7.3% during the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares during the period.

Pulmatrix Company Profile

(Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Featured Articles

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with's FREE daily email newsletter.